MNG922
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.641
- E2F_TARGETS+0.602
- G2M_CHECKPOINT+0.526
- UNFOLDED_PROTEIN_RESPONSE+0.519
- MYC_TARGETS_V1+0.489
- MTORC1_SIGNALING+0.452
- OXIDATIVE_PHOSPHORYLATION+0.413
- DNA_REPAIR+0.391
- MITOTIC_SPINDLE+0.361
- GLYCOLYSIS+0.340
Top 10 suppressed
- COAGULATION-0.329
- KRAS_SIGNALING_DN-0.303
- MYOGENESIS-0.269
- APICAL_SURFACE-0.236
- TGF_BETA_SIGNALING-0.232
- INTERFERON_ALPHA_RESPONSE-0.226
- BILE_ACID_METABOLISM-0.211
- ESTROGEN_RESPONSE_EARLY-0.160
- KRAS_SIGNALING_UP-0.159
- INTERFERON_GAMMA_RESPONSE-0.156
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030367_D1.RNA-Seq | EPN | Anaplastic EPN | 0.853 |
| 2 | SRR934893 | — | — | 0.851 |
| 3 | 0D600773-1B42-4F04-BCEA-39F658DF63F1 | — | — | 0.851 |
| 4 | E0DE33EA-C3DF-478E-9C4D-86E3C7B3A1D9 | — | — | 0.848 |
| 5 | EE4F9349-F750-4471-BFE7-7230784569E1 | — | — | 0.846 |
| 6 | SRR23036890 | — | — | 0.843 |
| 7 | DD5AA3F8-E3EE-4EDD-8152-B1CC07B70A08 | — | — | 0.842 |
| 8 | FB7673F7-FF7F-4C3C-A8C6-9C11C6BB71D5 | — | — | 0.835 |
| 9 | TCGA-39-5021-01A-01R-1443-07 | — | cohortSQ2 | 0.833 |
| 10 | MNG646 | — | — | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.641 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.602 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.526 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.519 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.489 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.452 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.413 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.391 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.361 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.340 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.309 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.245 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.164 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.124 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.113 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.109 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.088 | Inavolisib | — uncovered |